All News

Rather than looking back at what has been a challenging past few months, this Trend Report - featuring highlights from the Pharmapack 2021 content programme - has been written very much in the spirit of looking forward and addressing the key challenges...

Rise of innovative companies with high-risk portfolios will necessitate need for CDMOs, says Thermo Fisher senior executive

By completion at the end of 2022, the campus will accommodate 18 cGMP viral vector manufacturing suites

COVID-19 pandemic has exposed weaknesses and sector faces new challenges driven by rising costs of production in China

Current EU regulatory systems too overwhelmed by paper, head of European association representing generics, biosimilars and value added medicines industries tells CPHI Worldwide online conference

Country expected to grow threefold over the next decade due to increased focus on complex generics, biosimilars and specialty products

One site will focus on microbial production, the other on small-scale mammalian-based production

Milan is home to an internationally competitive pharmaceutical, biotechnology and functional foods hub, with strong growth prospects and a commitment to innovation across its entire supply chain. Italy is also home to one of the most advanced and ...

The CDMO will supply expertise in GMP sterile fill-finish manufacturing and controlled-substances

As a network member, the company hopes to help reduce the US's reliance on overseas imports by providing domestic API capability

According to unnamed sources in Politico report, company’s vaccine batches have not met FDA purity level standards

UCB Pharma is informed by agency that action on application for psoriasis treatment is being deferred until on-site visits can be made

In complete response letter, agency cites single deficiency at third-party facility that performs analytical testing of Treprostinil drug substance

Together the companies will attempt to overcome "black box" challenges to enable more robust and consistent results for clients

The move, coupled with the plants's passing of a pharmaceutical GMP compliance inspection, will enable company to accelerate the R&D of its novel Advanced TCMPs

The biologics CDMO says it expects its new 53,000-sq.ft facility will be operational within 18 months

Manufacturer starts development of API for molnupiravir, which is set to become world’s first oral treatment against coronavirus

Awards showcased a wide range of industry-changing innovations in packaging and drug delivery, with sustainability emerging as a key metric across all categories

Panel discusses how healthcare institutions are adapting to calls for more sustainability in various processes in the value chain

The transaction expands the CDMO's GMP biopharmaceutical and vaccine manufacturing capabilities

The new the 140,000-sq. ft facility will support commercialisation and industrialisation of viral vectors

Having acquired a 53,000 sq-ft property in Berlin, the company plans to set up new laboratories, production and cleanrooms

The COVID-19 pandemic has meant scientists, together with pharmaceutical companies, have had to reinvent how to bring vaccines to market faster without impacting product quality, safety, or efficacy, according to experts speaking at a recent CPHI webin...

Pre-filled syringes (PFS) could help immensely in solving the challenges of rolling out future mass vaccination campaigns, according to experts at Becton Dickinson (BD).

During the live Innovation in Connectivity Roundtable at the Pharmapack 2021 online conference, experts discussed how the latest innovations in digital technology are shaping industry ambitions to put the patient journey at the heart of its drug device...

The LSCC provides an additional 30% in mammalian large-scale capacity for the company's own pipeline and for third parties

Just as 'food miles' have become a key concern among consumers in recent years, patients now want to know more about 'medicine miles', study commissioned by Teva finds

Electronic devices and connectivity are being progressively included in drug delivery devices, bringing positive outcomes to all stakeholders, according to drug device combinations specialist, Nemera Tuesday

Traceability of medicines can help to reduce the negative effects to pharmaceutical supply chains of counterfeit medicines, medication errors and drug shortages, Nathalie Wardé-Dunoyer, CEO & Founder of Swiss start-up, D4P pharma told the Pharma...

The $85 million Iovance Cell Therapy Center (ICTC) has opened its doors at the Philadelphia Navy Yard with capacity to supply thousands of patients per year.

Quantum computing technology uses quantum systems called “qubits”. They work with non-binary values, unlike classical computing which uses only bits with values of 0 or 1, and can overlap each other and act as a group. The result is a ...

Responding to critical market capacity constraints, Thermo Fisher announces the official opening of new 67,000 sqft cGMP plasmid DNA manufacturing facility in Carlsbad, CA. This site expands clinical and commercial capabilities for cGMP plasmid DNA use...

By providing AAV process development, scale up and cGMP manufacturing services, Forge hopes to bolster Solid's gene therapy pipeline

The transaction will generate $102.25 million to support the company's product pipeline and scaling up commercial activities for Afrezza

New facility aims to serve local and global pharmaceutical customers with high-purity ethanol, ethanol blends and buffer solutions

Shawn Branning, Global Strategic Marketing Manager at IFF – Pharma Solutions

Catch up on the latest trends and developments in orally disintegrating tablet (ODT) formulation development

Biocatalytic processing offers a wealth of advantages and should be evaluated during early-stage drug development for its potential to improve yields, increase efficiency, and support greener manufacturing.

The facility will increase the production capacity of cell culture media products and provide a hub for European and global markets

In France, rare diseases are numerous: between 7,000 and 8,000 diseases are currently accounted for, and concern more than 3 million French people, accounting for almost 4,5% of the total population. The organization of screening and care for these ill...

The company plans to open a new 130,000-sq. ft plant in Ann Arbor in late 2023

The acquisition will add 13 approved products and additional pipeline products

Only 0.3% of the 5.76 billion doses administered worldwide have been distributed to low-income countries

The private investment firm plans to acquire SEQENS and merge it with Wavelength Pharmaceuticals

Pharmapack Europe is back! Join us online from 27 September as we kick off our two-week long content programme, a great precursor to the in-person event from 13-14 October at the Paris Expo Porte de Versailles.

As a safe, effective and convenient way to administer injectable medications, pre-filled syringes (PFS) have become the injection system of choice for a growing number of drugs. PFS allow healthcare professionals to easily handle syringes, reduce waste...

The company's new Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline transition from research to clinical environments

The CDMO will provide commercial manufacturing and packaging services for Phathom's novel, orally active P-CAB

The transaction is expected to accelerate Catalent's growth in global softgel and oral dose formulation and manufacturing services

Today, Informa Markets is pleased to announce the launch of the all-new CPHI Online Dashboard, which will allow CPHI clients to quickly and easily track awareness and interest in their company, products and content as well as view and download leads to...

The expansion is anticipated to speed up development and time-to-market of novel treatments and vaccines for COVID‑19

The expansion plans include an additional manufacturing line, a new cleanroom and a new process development lab

As CDMOs seek to diversify their business models, is a full-service offering the holy grail or is there a danger of biopharmaceutical outsourcing firms becoming the jack of all trades and the master of none?

Investment will further expand CDMO's global network of SUT facilities to boost reliable supply of critical materials used to produce new biologics and vaccines

Sponsors within the biopharmaceutical industry are increasingly turning to outsourcing for several reasons; remaining competitive and flexible within a quickly evolving sector, gaining access to manufacturing capacity and state-of-the-art equipment and...

Opportunities for CDMO expansion are extending to Latin America and Africa, say experts

The CDMO will manufacture drug substance and drug product for Phase II clinical trials in AML patients

Japan's biggest drugmaker prepares to make the vaccine domestically and anticipates early 2022 distribution

Taking a sterile drug product from clinical to commercial scale brings unique challenges. In this article, LLS Health investigates ways to mitigate scale-up challenges and achieve success.

The CDMO significantly increases its footprint, capacity and capabilities to meet current and future demand

The new Switzerland-based CDMO differentiates itself by its sustainable vision of making a positive impact for people and planet

Companies say earlier collaboration may speed development and introduction of targeted precision medicine therapies for patients.

The facility will be able to manufacture and stockpile a five-year supply of amoxicillin for the US

In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected...

The agreement is expected to accelerate Cipla’s global lung leadership agenda

£35 million public-private collaboration to develop next-generation pharmaceutical manufacturing processes to drive forward innovation in the medicines supply chain

The CDMO inaugurates its new analytical laboratory under Recipharm Analytical Solutions

The new facility will augment the company's capacity to broaden its portfolio of perinatal-derived products

Pfizer and BioNTech’s shot on Monday became the first COVID-19 vaccine to be granted full approval by the US Food and Drug Administration.

The new production line at Guangzhou site will supply global and domestic companies with clinical and commercial batches

An update on responsible supply chain management from the Pharmaceutical Supply Chain Initiative Chair, Manjit Singh

mRNA (Messenger ribonucleuc acid) technology has been thrust into the limelight in recent months, with the platform proving to be the springboard for two approved vaccines against the SARS-CoV-2 virus.

The $35 million investment will more than double the site’s batch-size scaling and product output.

New site in Cardiff boosts the company's production capacity for equipment crucial in the supply chain for mRNA vaccines production

Firms say the partnership will "multiply the power of both companies, the pharmaceutical industry and the medical cannabis industry"

The capital will be used to expand and industrialise the company's range of single-use bioreactor systems and contract process development services

COVID-19 has focused a spotlight on the ability of mRNA technology to accelerate vaccine development and approval. That same technology can hasten the development and approval of other therapeutic classes, including cancer immunotherapy, protein replac...

The solid oral dose specialist signs letter of intent for acquisition of a CDMO providing a full range of services

The new facility will provide access to domestically manufactured vaccines against respiratory viruses

Innovation is the cornerstone of the drug delivery technology sector; efforts to make therapies more convenient for patients, reduce side effects and differentiate products from the competition have always made the delivery sector a hotbed of new ideas...

The CPHI North America exhibition is taking place in-person this week in Philadelphia from 10-12 August. Here we take a look at key learnings from the past two weeks of expert-led content, available to all attendees as part of the hybrid event experien...

KYOWA Pharmaceutical Industry will be the CDMO's first Japanese client for its Zhunan manufacturing site

Dependence on Asia – and specifically China – has been the subject of a great deal of attention by political and industry leaders in the last year. In North America, this has led to calls to “reshore” drug production to domestic facilities.

The cosmetics packaging sector will need to respond to increasing consumer awareness of climate change by transitioning from fossil-based materials to long-term carbon neutral and carbon negative alternatives, according to industry experts speaking at ...

Tech transfer is a crucial phase that converts clinical promise into commercial gain but pressure on sponsors to reduce time to market in the age of COVID-19 means CDMOs have to be on top of their game to deliver. What are the latest innovations to sol...

The collaboration will see Catalent install a commercial-scale KinetiSol technology manufacturing line at its Somerset, New Jersey, facility

The purchase of BMS's Couvet, Switzerland facility adds commercial-scale production capacity for capsule and tablet dosage forms

Explore the series of Learning Labs at CPHI North America in which thought leaders at our exhibitors showcase their extensive knowledge on all areas of the pharma supply chain, offering industry insights across drug manufacturing, outsourcing, pharma i...

The new approval of Semeglee allows pharmacy-level substitution for Lantus across the US

Explore the series of Learning Labs at CPHI North America across several product innovation categories in which thought leaders at our exhibitors showcase their extensive expertise in all areas of the pharma supply chain, offering industry insight...

Opportunities for contract development and manufacturing organisations (CDMOs) in China continue to grow but many questions remain over what the future of the sector will look like in the world's second largest pharmaceutical market.

CDMOs need to diversify and expand their capabilities to take full advantage of strong growth in prominent end markets such as small molecule, monoclonal antibodies and cell and gene therapy, according to an industry expert on a panel at the CPHI North...

Acquiring Xell AG will enable Sartorius to offer specialised media for manufacturing viral vectors

Speaking at CPHI North America, Dr Scott Gottlieb shares insights into how the US should prepare for future pandemics by building out vaccine capacities

Transformative technologies and the opportunities afforded by the COVID-19 pandemic have spurred investment in the life sciences outsourcing sector, according to a panel of industry experts speaking at CPHI North America on Monday.

Accelerated efforts align with the Paris Agreement and Race To Zero to combat climate change

More than 350,000 health apps are currently available, increasingly focused on helping them manage their conditions rather than on wellness management

The rise in the concept of ‘self-care’ has forced the beauty and cosmetics industry to think differently about how they launch their products. Martin Oxley, Managing Director at buzzback explains why the cosmeceuticals sector does not just ...

As more and more companies operating in the pharmaceutical space are moving into cosmetics, the temptation is to think that life will be much easier from a regulatory and compliance perspective.

Two 2,000-liter single-use bioreactors to be installed as part of first phase expected to be operational in April 2023

The investment will fund the construction of a Translational Science Center for its Healthcare business sector, as well as a new Learning Center

The acquisition will add manufacturing footprint in the US enabling the company to develop its pipeline of novel cancer product candidates

Samsung to provide end-to-end CDMO services to advance Kineta's novel anti-VISTA antibody for the treatment of solid tumours

Cannabinoids have caught the attention of Pharma and Cosmetic companies alike in recent years, celebrated for their anti-inflammatory, anti-oxidant and anti-bacterial properties in cosmetic products, and neurological and chronic pain benefits on the ph...

Using Veratrak's platform, the CDMO will have full oversight of data, including an audit trail of data and document processes

67,000-square-foot facility at Carlsbad campus is part of CDMO's investment strategy that addresses growing global demand for cell and gene therapies and vaccines

Acquisition will add West Coast coverage to the CDMO's East Coast and European capabilities and enhance its biologics formulation development and fill-finish network

The company will use its orally disintegrating tablet technology Zydis for JOS Pharmaceuticals' licensed CBD product

The emerging biotech company unveils plans for a 1.2 million-sq. ft manufacturing facility in Yangzhou

The integrated CDMO rolls out services to the broader community of drug manufacturers and developers

Healthcare provision is constantly evolving. Whereas in the past, decision making on treatments for patients was very much the domain of physicians and doctors, patients now feel more empowered to be involved in the decision making process. The healthc...

A new media panel, gene kit and advanced resins help reduce manufacturing costs and increase the viability of gene therapies

Pharma firm tells FDA tech transfer to its own facility in Schaftenau, Austria is underway after regulator highlighted concerns about third party CDMO site in Italy

Biogen’s Alzheimer’s drug Aduhelm has recently secured FDA approval to much fanfare. But do the benefits of the treatment justify the weighty $56,000 per year price tag?

For pharma manufacturers and service providers, attending face-to-face events and exhibitions has always been a crucial tool for meeting existing clients, signing contracts, and gathering leads for new business. But with events unable to trade over the...

Watch this CPHI Webinar sponsored by PharmaVentures, in which a broad panel of experts across the pharmaceutical manufacturing space discussed how M&A activity is being shaped by this ever evolving and complex sector

Move is part of US$500 million five-year investment programme by Moroccan government and consortium to establish vaccine and biotherapeutic manufacturing capacity in the country

Medalchemy facility now fully licensed to import, cultivate, extract, manufacture and export medical cannabis flower and extracts

The CDMO's fivefold capacity increase will provide early preclinical through to commercialisation support

Greenfield construction of the new facility is expected to start later this year